[go: up one dir, main page]

EP2568811A4 - Treatment of mci and alzheimer's disease - Google Patents

Treatment of mci and alzheimer's disease

Info

Publication number
EP2568811A4
EP2568811A4 EP10851531.3A EP10851531A EP2568811A4 EP 2568811 A4 EP2568811 A4 EP 2568811A4 EP 10851531 A EP10851531 A EP 10851531A EP 2568811 A4 EP2568811 A4 EP 2568811A4
Authority
EP
European Patent Office
Prior art keywords
mci
alzheimer
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10851531.3A
Other languages
German (de)
French (fr)
Other versions
EP2568811A1 (en
Inventor
Mark Lovell
Bert Lynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/034721 external-priority patent/WO2010132671A1/en
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Publication of EP2568811A1 publication Critical patent/EP2568811A1/en
Publication of EP2568811A4 publication Critical patent/EP2568811A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10851531.3A 2010-05-13 2010-11-18 Treatment of mci and alzheimer's disease Withdrawn EP2568811A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease
PCT/US2010/057287 WO2011142778A1 (en) 2010-05-13 2010-11-18 Treatment of mci and alzheimer's disease

Publications (2)

Publication Number Publication Date
EP2568811A1 EP2568811A1 (en) 2013-03-20
EP2568811A4 true EP2568811A4 (en) 2014-03-12

Family

ID=44923820

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10851531.3A Withdrawn EP2568811A4 (en) 2010-05-13 2010-11-18 Treatment of mci and alzheimer's disease

Country Status (6)

Country Link
EP (1) EP2568811A4 (en)
JP (1) JP2013526518A (en)
CN (1) CN102984938A (en)
AU (1) AU2010353287A1 (en)
CA (1) CA2799162A1 (en)
WO (1) WO2011142778A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6424210B2 (en) * 2013-05-06 2018-11-14 バクスアルタ インコーポレイテッド Treatment of a subpopulation of Alzheimer's disease with pooled immunoglobulin G
US20160333006A1 (en) * 2014-01-29 2016-11-17 Bristol-Myers Squibb Company Aryl lacta kinase inhibitors
CN106177046A (en) * 2016-08-29 2016-12-07 杨添福 A kind of nervus cognition disorder medicine based on the exploitation of Pu Lining potassium and preparation method thereof
CN106645505A (en) * 2016-11-18 2017-05-10 中国医科大学 Kit capable of implementing identification and absolute quantification of GLT-1 (glutamate transporter-1) protein and determination method
CN107022019B (en) * 2016-11-24 2020-10-30 桂林医学院 A kind of polypeptide for reducing iron in brain and removing free radicals, preparation method and application
CN106636388A (en) * 2016-12-15 2017-05-10 湖南中能荆卫生物科技有限公司 Gene for huntington disease diagnosis and application of gene, protein coded by gene and application of protein
CN108191966B (en) * 2018-01-11 2020-10-27 桂林医学院 A polypeptide containing a guide peptide that can cross the blood-brain barrier and chelate iron in the brain to reduce free radicals
JP2022516574A (en) * 2019-01-07 2022-02-28 センナ バイオサイエンシーズ インク． New peptides and their use
JP7321017B2 (en) * 2019-07-17 2023-08-04 東海物産株式会社 functional food

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028761A1 (en) * 1999-08-16 2002-03-07 Koppel Gary A. Neurotherapeutic use of carboxypeptidase inhibitors
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2010108052A2 (en) * 2009-03-20 2010-09-23 H. Lundbeck A/S Amide derivatives as neuropeptide y5 receptor ligands

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8002A (en) * 1851-03-25 Upright pianoforte
DE2126533A1 (en) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Process for the production of pharmaceutical preparations
WO1999051277A1 (en) * 1998-04-08 1999-10-14 Oregon Health Sciences University Enhancement of cellular gallium uptake
AU2001224250A1 (en) * 2000-11-21 2002-06-03 Howard Zik Therapy for herpes neurological viral conditions utilizing 1,4-dihydropyridine calcium channel blockers
ATE399026T1 (en) * 2003-11-21 2008-07-15 Memory Pharm Corp COMPOSITIONS CONTAINING L-TYPE CALCIUM CANAL BLOCKERS AND CHOLINESTERASE INHIBITORS
EP1874311B1 (en) * 2005-04-15 2011-10-05 Research & Innovation S.p.A. A method for preventing, delaying or reverting abnormal amyloid deposition
WO2007064010A1 (en) * 2005-12-02 2007-06-07 Mochida Pharmaceutical Co., Ltd. Preventive/therapeutic agent for alzheimer's dementia
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
CA2648243C (en) * 2006-04-11 2015-12-22 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20080293712A1 (en) * 2007-03-05 2008-11-27 Wyeth Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028761A1 (en) * 1999-08-16 2002-03-07 Koppel Gary A. Neurotherapeutic use of carboxypeptidase inhibitors
WO2010034110A1 (en) * 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2010108052A2 (en) * 2009-03-20 2010-09-23 H. Lundbeck A/S Amide derivatives as neuropeptide y5 receptor ligands

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DONG H. KIM: "Rearrangements of 4-(2-Aminophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 23, no. 5, 1 September 1986 (1986-09-01), US, pages 1471 - 1474, XP055100273, ISSN: 0022-152X, DOI: 10.1002/jhet.5570230543 *
DONNA L SAVIGNI ET AL: "Iron and transition metal transport into erythrocytes mediated by nifedipine degradation products and related compounds", BIOCHEMICAL PHARMACOLOGY, vol. 65, no. 8, 1 April 2003 (2003-04-01), pages 1215 - 1226, XP055100193, ISSN: 0006-2952, DOI: 10.1016/S0006-2952(03)00045-5 *
GÖRLITZER K ET AL: "3,6-Diazaphenanthrene aus Nifedipin", ARCHIV DER PHARMAZIE, WILEY VERLAG, WEINHEIM, vol. 318, no. 2, 1 February 1985 (1985-02-01), pages 97 - 105, XP002668333, ISSN: 0365-6233 *
GÖRLITZER K ET AL: "9-Chlor-3,6-diazaphenanthrene aus Nifedipin", ARCHIV DER PHARMAZIE, WILEY VERLAG, WEINHEIM, vol. 318, no. 2, 1 January 1985 (1985-01-01), pages 106 - 110, XP002668334, ISSN: 0365-6233 *
KAMETANI T ET AL: "NITRENES. PART III. THE REACTION OF 4-(2-NITROPHENYL)PYRIDINE DERIVATIVES WITH TRIETHYL PHOSPHITE", JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY, CHEMICAL SOCIETY. LETCHWORTH, GB, 1 January 1969 (1969-01-01), pages 138 - 140, XP009004598, ISSN: 0022-4952, DOI: 10.1039/J39690000138 *
PETROW V A: "New Syntheses of Heterocyclic Compounds. Part VIII. The Schmidt Rearrangement of 1 : 3-Dimethyl-2-azafluorenones (continued)", JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL SOCIETY, LETCHWORTH; GB, 1 January 1946 (1946-01-01), pages 888 - 891, XP002668516, ISSN: 0368-1769 *
See also references of WO2011142778A1 *

Also Published As

Publication number Publication date
JP2013526518A (en) 2013-06-24
CN102984938A (en) 2013-03-20
CA2799162A1 (en) 2011-11-17
EP2568811A1 (en) 2013-03-20
WO2011142778A1 (en) 2011-11-17
AU2010353287A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
IL287794A (en) Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
EP2429992A4 (en) Treatment of mci and alzheimer's disease
IL237369A0 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
EP2568811A4 (en) Treatment of mci and alzheimer's disease
IL217768A0 (en) Treatment of crohn's disease with laquinimod
EP2707369A4 (en) Compositions and methods for treating alzheimer's disease
PL2104682T3 (en) Diagnosis and treatment of alzheimer's and other neurodementing diseases
EP3628326C0 (en) Methods and materials for treatment of pompe's disease
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
GB2496801B (en) A method of treating alzheimer's disease
IL260078B (en) Therapy for use for the treatment of gaucher's disease
IL230441A0 (en) Diagnosis of alzheimer's disease
IL237730B (en) Treatment of mild and moderate alzheimer's disease
EP2660600A4 (en) Diagnostic drug and diagnostic method for alzheimer's disease
EP2391379A4 (en) Compound and method for treatment of alzheimer's disease
PL2565184T3 (en) Therapeutic agent and preventative agent for alzheimer's disease
EP2413696A4 (en) Compositions for treatment of alzheimer's disease
EP2480099A4 (en) Compositions and methods for the prevention and treatment of metabolic diseases
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
EP2613849A4 (en) RADIOTHERAPY TO TREAT ALZHEIMER'S DISEASE
GB201018362D0 (en) Treatment of dupuytren's disease
GB0811555D0 (en) Treatment of Alzheimer's disease
GB201101088D0 (en) L-carnosine and cinnamon extract for the treatment of Alzheimer's Disease
GB201113718D0 (en) Treatment of Dupuytren's Disease
IL214340A0 (en) Methods and compositions for treating alzheimer's disease

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1183408

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20140211

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 43/40 20060101AFI20140205BHEP

Ipc: A61P 25/28 20060101ALI20140205BHEP

Ipc: A61K 31/4375 20060101ALI20140205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160601

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1183408

Country of ref document: HK